Adenovirus serotype 5 L4-22K and L4-33K proteins have distinct functions in regulating late gene expression

Journal of Virology

Volumn 83, Issue 7, 2009, Pages 3049-3058

  Morris, Susan J ^a   Leppard, Keith N ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS 5 L4 22K PROTEIN; ADENOVIRUS 5 L4 33K PROTEIN; MESSENGER RNA; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR; VIRUS PROTEIN;

ADENOVIRUS 5; AMINO ACID SEQUENCE; ARTICLE; CODON; GENE EXPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RNA SPLICING; UPREGULATION; VIRUS GENOME; VIRUS REPLICATION; WILD TYPE; ADENOVIRUS; GENE EXPRESSION REGULATION; GENETIC COMPLEMENTATION; METABOLISM; PHYSIOLOGY; STOP CODON;

ADENOVIRIDAE;

ADENOVIRIDAE; CODON, NONSENSE; GENE EXPRESSION REGULATION, VIRAL; GENETIC COMPLEMENTATION TEST; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 63149098787     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02455-08     Document Type: Article

References (46)

1. Akusjarvi, G. 2008. Temporal regulation of adenoviras major late alternative RNA splicing. Frontiers Biosci. 13:5006-5015.
2. Ali, H., G. LeRoy, G. Bridge, and S. J. Flint. 2007. The adenoviras L4 33-kilodalton protein binds to intragenic sequences of the major late pro moter required for late phase-specific stimulation of transcription. J. Virol. 81:1327-1338.
3. Arslanoglu, A. 1999. Studies of adenovirus L1 gene aimed at L1 gene defi ciencies for use in gene therapy vectors. Ph.D. thesis. University of Warwick, Coventry, United Kingdom.
4. Brey, S. 1999. Construction of IVa2-deficient adenoviras using complement ing cell lines. Ph.D. thesis, University of Warwick, Coventry, United King dom.
5. Caravokyri, C, and K. N. Leppard. 1995. Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenoviras type 5. J. Virol. 69:6627-6633.
6. Cepko, C. L., and P. A. Sharp. 1982. Assembly of adenovirus major capsid protein is mediated by a nonvirion protein. Cell 31:407-415.
7. Chang, L. S., and T. Shenk. 1990. The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenoviras and adeno-associated virus promoters. J. Virol. 64:2103-2109.
8. Chartier, C, E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenoviras vectors by homologous recombination in Escherichia coli. J. Virol. 70:4805-4810.
9. Chen, H., R. Vinnakota, and S. J. Flint. 1994. Intragenic activating and repressing elements control transcription from the adenoviras IVa2 initiator. Mol. Cell. Biol. 14:676-685
10. Crossland, L. D., and H. J. Raskas. 1983. Identification of adenovirus genes that require template replication for expression. J. Virol. 46:737-748.
11. Davison, A. J., M. Benko, and B. Harrach. 2003. Genetic content and evolution of adenoviruses. J. Gen. Virol. 84:2895-2908.
12. Farley, D. C, J. L. Brown, and K. N. Leppard. 2004. Activation of the early-late switch in adenovirus type 5 major late transcription unit expression by L4 gene products. J. Virol. 78:1782-1791.
13. Fessler, S. P., and C. S. H. Young. 1999. The role of the L4 33K gene in adenovirus infection. Virology 263:507-516.
14. Finnen, R. L., J. F. Biddle, and J. Flint. 2001. Truncation of the human adenovirus type 5 L4 33-kDa protein: evidence for an essential role of the carboxy-terminus in the viral infectious cycle. Virology 289:388-399.
15. Gustin, K. E., P. Lutz, and M. J. Imperiale. 1996. Interaction of the adeno virus L1 52/55-kilodalton protein with the IVa2 gene product during infec tion. J. Virol. 70:6463-6467.
16. Hardy, S., M. Kitamura, T. Harris-Stansil, Y. Dai, and M. L. Phipps. 1997. Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71:1842-1849.
17. Hayes, B. W., G. C. Telling, M. M. Myat, J. F. Williams, and S. J. Flint. 1990. The adenovirus L4 100-kilodalton protein is necessary for efficient transla tion of viral late mRNA species. J. Virol. 64:2732-2742.
18. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
19. Iftode, C, and S. J. Flint. 2004. Viral DNA synthesis-dependent titration of a cellular repressor activates transcription of the human adenovirus type 2 IVa2 gene. Proc. Natl. Acad. Sci. USA 101:17831-17836.
20. Jansen-Durr, P., G. Mondesert, and C. Kedinger. 1989. Replication-depen dent activation of the adenovirus major late promoter is mediated by the increased binding of a transcription factor to sequences in the first intron. J. Virol. 63:5124-5132.
21. Jones, N., and T. Shenk. 1978. Isolation of deletion and substitution mutants of adenovirus type 5. Cell 13:181-188.
22. Larsson, S., C. Svensson, and G. Akusjarvi. 1992. Control of adenovirus major late gene expression at multiple levels. J. Mol. Biol. 225:287-298.
23. Lethbridge, K. J., G. E. Scott, and K. N. Leppard. 2003. Nuclear matrix localization and SUMO-1 modification of adenovirus type 5 E1b 55K protein are controlled by E4 Orf6 protein. J. Gen. Virol. 84:259-268.
24. Lin, H. J., and S. J. Flint. 2000. Identification of a cellular repressor of transcription of the adenoviral late IVa(2) gene that is unaltered in activity in infected cells. Virology 277:397-410.
25. Lutz, P., and C. Kedinger. 1996. Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter. J. Virol. 70:1396-1405.
26. Lutz, P., M. Rosa-Calatrava, and C. Kedinger. 1997. The product of the adenovirus intermediate gene IX is a transcriptional activator. J. Virol. 71:5102-5109.
27. Michou, A. I., L. Santoro, M. Christ, V. Julliard, A. Pavirani, and M. Mehtali. 1997. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 4:473-482.
28. Mondesert, G., C. Tribouley, and C. Kedinger. 1992. Identification of a novel downstream binding protein implicated in late-phase-specific activation of the adenovirus major late promoter. Nucleic Acids Res. 20:3881-3889.
29. Morris, S. J., H. Smith, and C. Sweet. 2002. Exploitation of the herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role. Arch. Virol. 147:961-979.
30. Nevins, J. R., and M. C. Wilson. 1981. Regulation of adenovirus-2 gene expression at the level of transcriptional termination and RNA processing. Nature 290:113-118.
31. Ostapchuk, P., M. E. Anderson, S. Chandrasekhar, and P. Hearing. 2006. The L4 22-kilodalton protein plays a role in packaging of the adenovirus genome. J. Virol. 80:6973-6981.
32. Pardo-Mateos, A., and C. S. Young. 2004. Adenovirus IVa2 protein plays an important role in transcription from the major late promoter in vivo. Virol ogy 327:50-59.
33. Philipson, L. 1961. Adenovirus assay by the fluorescent cell-counting proce dure. Virology 15:263-268.
34. Reich, N. C, P. Sarnow, E. Duprey, and A. J. Levine. 1983. Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology 128:480-484.
35. Russell, W. C. 2000. Update on adenovirus and its vectors. J. Gen. Virol. 81:2573-2604.
36. Russell, W. C, G. Patel, B. Precious, I. Sharp, and P. S. Gardner. 1981. Monoclonal antibodies against adenovirus type 5: preparation and prelimi nary characterization. J. Gen. Virol. 56:393-408.
37. Soloway, P. D., and T. Shenk. 1990. The adenovirus type 5 i-leader open reading frame functions in cis to reduce the half-life of L1 mRNAs. J. Virol. 64:551-558.
38. Symington, J. S., L. A. Lucher, K. H. Brackmann, A. Virtanen, U. Pettersson, and M. Green. 1986. Biosynthesis of adenovirus type 2 i-leader protein. J. Virol. 57:848-856.
39. Tormanen, H., E. Backstrom, A. Carlsson, and G. Akusjarvi. 2006. L4-33K, an adenoviras-encoded alternative RNA splicing factor. J. Biol. Chem. 281: 36510-36517.
40. Tribouley, C., P. Lutz, A. Staub, and C. Kedinger. 1994. The product of the adenovirus intermediate gene IVa2 is a transcriptional activator of the major late promoter. J. Virol. 68:4450-4457.
41. Yang, J., T. Tsukamoto, N. Popnikolov, R. C. Guzman, X. Chen, J. H. Yang, and S. Nandi. 1995. Adenoviral-mediated gene transfer into primary human and mouse mammary epithelial cells in vitro and in vivo. Cancer Lett. 98:9-17.
42. Yang, Y., H. C. Ertl, and J. M. Wilson. 1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immunity 1:433-442.
43. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits El-deleted adeno viruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
44. Zabner, J., L. A. Couture, R. J. Gregory, S. M. Graham, A. E. Smith, and M. J. Welsh. 1993. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207-216.
45. Zhang, W., and M. J. Imperiale. 2000. Interaction of the adenovirus IVa2 protein with viral packaging sequences. J. Virol. 74:2687-2693.
46. Zhang, W., J. A. Low, J. B. Christensen, and M. J. Imperiale. 2001. Role for the adenovirus IVa2 protein in packaging of viral DNA. J. Virol. 75:10446-10454.